COVID-19 Outbreak-Global Neurogenic Orthostatic Hypotension Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
- 120 Pages
- Region: Global
Neurogenic orthostatic hypotension (also referred to as neurogenic OH or nOH) is a rare disorder that is defined as low blood pressure that occurs upon standing. NOH is a sub-type of orthostatic hypotension (OH). With NOH and other forms of orthostatic hypotension, patients experience the same symptoms but for different reasons. NOH only occurs in people with an existing neurologic disease, such as: Multiple system atrophy (MSA), Parkinson’s disease, Pure autonomic failure (PAF), Diabetic neuropathy, Dopamine beta hydroxylase (DBH) deficiency.
The Neurogenic Orthostatic Hypotension market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.
Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.
In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Neurogenic Orthostatic Hypotension industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.
The Neurogenic Orthostatic Hypotension market can be split based on product types, major applications, and important countries as follows:
Key players in the global Neurogenic Orthostatic Hypotension market covered in Chapter 12:
Chelsea Therapeutics (Droxidopa)
Shire PLC (ProAmatine®)
In Chapter 4 and 14.1, on the basis of types, the Neurogenic Orthostatic Hypotension market from 2015 to 2025 is primarily split into:
Dopamine beta hydroxylase (DBH) deficiency
In Chapter 5 and 14.2, on the basis of applications, the Neurogenic Orthostatic Hypotension market from 2015 to 2025 covers:
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
Europe (Covered in Chapter 8 and 14)
Asia-Pacific (Covered in Chapter 9 and 14)
Middle East and Africa (Covered in Chapter 10 and 14)
South America (Covered in Chapter 11 and 14)
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025